Edimer Pharmaceuticals and CMC Biologics entered in to a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

CMC Biologics was selected by Edimer for their lead product due to its depth of expertise in protein development, analytical development and its cGMP manufacturing capabilities. According to Neil Kirby, CEO, Edimer,  "CMC's extensive experience in the GMP manufacture of therapeutic proteins makes them an ideal company to help us move this product forward. We believe that this product has the potential for making a difference in individuals' lives that currently have no available therapeutic options."

Gustavo Mahler, chief operating officer, CMC Biologics expressed, "CMC is delighted to be able to assist Edimer in the development and production of this orphan protein. Our two teams are working together in an open and collaborative manner and we are excited about the project's potential."

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy individuals that is involved in the formation of sweat glands, teeth, hair and certain glandular structures. This protein is missing in patients with XLHED. EDI200 is a form of EDA-A1 being developed by Edimer as a treatment for certain patients with XLHED. EDI200 has been shown to substitute for lack of functional EDA-A1 protein in mouse and dog models of XLHED.